<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004287</url>
  </required_header>
  <id_info>
    <org_study_id>199/11715</org_study_id>
    <secondary_id>UPHS-28051</secondary_id>
    <nct_id>NCT00004287</nct_id>
  </id_info>
  <brief_title>Phase I Study of the Third Generation Adenovirus H5.001CBCFTR in Patients With Cystic Fibrosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Assess the safety and feasibility of gene transfer with the third generation adenovirus
      H5.001CBCFTR in patients with cystic fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: H5.001CBCFTR, an adenovirus vector containing the cystic fibrosis
      transmembrane conductance regulator gene, is administered endobronchially.

      Cohort of 2 patients receive 1 of 6 H5.001CBCFTR concentrations. There is no intrapatient
      dose escalation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1995</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>14</enrollment>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>H5.001CBCFTR</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Cystic fibrosis diagnosed as follows: Sweat sodium or chloride
        greater than 60 mEq/L by pilocarpine iontophoresis or cystic fibrosis genotype Clinical
        manifestations Estimated 2-year survival greater than 50%, i.e.: FEV1 at least 30% of
        predicted PaO2 greater than 55 mm Hg on room air PaCO2 less than 50 mm Hg on room air
        --Prior/Concurrent Therapy-- At least 2 months since systemic glucocorticoids At least 90
        days since participation in investigational therapeutic study --Patient Characteristics--
        Pulmonary: No pneumothorax within 12 months No asthma or allergic bronchopulmonary
        aspergillosis requiring glucocorticoids within 2 months No sputum pathogens unless
        sensitive to at least 2 antibiotics No hemoptysis of more than 250 mL blood over 24 hours
        within 1 year Other: No active adenoviral infection Ad5 (or similar type) antibody
        seropositive No other contraindication to protocol participation, e.g.: Drug abuse
        Alcoholism Psychiatric instability Inadequate motivation Documented azoospermia (men)
        Bilateral tubal ligation or hysterectomy (women) Screening exams within 4 weeks prior to
        registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James M. Wilson</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <reference>
    <citation>Zuckerman JB, Robinson CB, McCoy KS, Shell R, Sferra TJ, Chirmule N, Magosin SA, Propert KJ, Brown-Parr EC, Hughes JV, Tazelaar J, Baker C, Goldman MJ, Wilson JM. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther. 1999 Dec 10;10(18):2973-85.</citation>
    <PMID>10609658</PMID>
  </reference>
  <verification_date>January 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>cardiovascular and respiratory diseases</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

